Identification
- Summary
Edaravone is a free radical scavenger used to delay the progression of ALS.
- Brand Names
- Radicava
- Generic Name
- Edaravone
- DrugBank Accession Number
- DB12243
- Background
Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties.5 It has three tautomers.3 Edaravone works to scavenge reactive oxygen species, which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.3,11,5
The intravenous formulation of edaravone was first approved in Japan in 2001 for the treatment of acute ischemic stroke.11 It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 6 and Health Canada approval in October 2018.11 The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.13
Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 11 and was under regulatory review in Europe. However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made by the Committee for Medicinal Products for Human Use (CHMP) for a long-term study demonstrating the long-term efficacy and safety of edaravone.10,12 Edaravone was also investigated in other disorders, such as Alzheimer's disease,1 neuropathic pain, and ischemia-induced nerve injury.2
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Edaravone (DB12243)
- Weight
- Average: 174.203
Monoisotopic: 174.07931295 - Chemical Formula
- C10H10N2O
- Synonyms
- 1-phenyl-3-methyl-5-oxo-2-pyrazoline
- 2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
- 3-methyl-1-phenyl-2-pyrazolin-5-one
- 3-methyl-1-phenyl-5-pyrazolone
- 3-methyl-1-phenylpyrazol-5-one
- Edaravone
- Methylphenylpyrazolone
- Norphenazone
- Phenyl methyl pyrazolone
- Phenylmethylpyrazolone
- External IDs
- MCI-186
- NSC-12
- NSC-26139
- NSC-2629
- TW001
Pharmacology
- Indication
Edaravone is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in the US and Canada.6,7 It is also indicated to treat acute ischemic stroke in Japan.3,4,11
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Edaravone works to delay the disease progression of neurological disorders such as ischemic stroke and ALS by limiting the extent of neuronal damage or death.3
- Mechanism of action
Oxidative stress and reactive oxygen species (ROS) production have been implicated in various neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.3,11,5 Oxidative stress caused by excess ROS damages endothelial cells in the cerebral vasculature as well as neuronal cell membranes, leading to neuronal cell death.3
Edaravone is a free radical scavenger that scavenges and suppresses the generation of hydroxyl radicals and peroxynitrite radicals.3 The exact mechanism of action of edaravone in ALS has not been fully elucidated; however, edaravone is thought to mediate therapeutic effects via its antioxidant properties. Since oxidative stress has been implicated in the pathophysiology of ALS and cerebral ischemia, inhibiting lipid peroxidation, suppressing endothelial cell damage induced by lipid peroxides, and scavenging free radicals may lead to neuroprotective effects.2 Edaravone has no effect on superoxide production.2,3 It is suggested that edaravone may also possess anti-inflammatory properties, as it inhibited neutrophil activation and suppressed inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) expression in animal models. It was also shown to ameliorate ROS-induced inflammatory oxidative stress after ischemic brain reperfusion.3
- Absorption
One study investigated the absorption of edaravone in healthy adults, who either received a single oral (105 mg/mL) or intravenous (60 mg/60 min) dose. The mean Cmax (CV%) and Tmax were 1656 (44.3) ng/mL and 0.5 hours, respectively, following oral administration.7 The absolute oral bioavailability is about 57% because of first-pass metabolism.6
The mean Cmax (CV%) and Tmax were 1253 (18.3) ng/mL and one hour, respectively, following intravenous administration.7 When intravenously administered, the maximum plasma concentration (Cmax) of edaravone was reached by the end of infusion.6
The Cmax and area under the concentration-time curve (AUC) of edaravone increases more than dose-proportional over the dose range of 30 to 300 mg. Edaravone does not accumulate in plasma with once-daily or multiple-dose administration. The Cmax and AUC decreased when the oral suspension formulation of edaravone was administered with a high-fat meal.7
- Volume of distribution
After intravenous administration, edaravone has a mean volume of distribution of 63.1 L, suggesting substantial tissue distribution. Edaravone has an apparent volume of distribution of 164 L following oral administration.7 Edaravone readily crosses the blood-brain barrier.4
- Protein binding
Edaravone is 92% bound to human serum proteins, mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L.6
- Metabolism
The metabolites of edaravone have not been fully characterized. Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases. Oral edaravone results in 1.3- and 1.7-fold higher exposures for both sulfate and glucuronide metabolites, respectively, when compared to intravenously-administered edaravone because of first-pass metabolism.6
- Route of elimination
In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and <1% of the dose was recovered in the urine as the unchanged drug. _In vitro_ studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine.6
- Half-life
The mean terminal elimination half-life of edaravone is approximately 4.5 to nine hours. The half-lives of its metabolites range from three to six hours.6
- Clearance
Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h.6 The apparent total clearance of edaravone is estimated to be 67.9L/h following oral administration.7
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Oral and intravenous LD50 in rats are 1915 mg/kg and 631 mg/kg, respectively.9 There is limited information on the acute toxicity of edaravone.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take on an empty stomach. RADICAVA ORS should be taken in the morning on an empty stomach after overnight fasting. Food should not be consumed for 1 hour after administration except water. The higher the fat content of the previous meal, the longer the fasting time before taking RADICAVA ORS will be.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Arone (Edinburgh Pharmaceuticals (India)) / Radicut (Mitsubishi Tanabe Pharma Corporation)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Radicava Injection 60 mg/100mL Intravenous Mitsubishi Tanabe Pharma America, Inc. 2020-05-05 Not applicable US 
Radicava Injection 30 mg/100mL Intravenous Mitsubishi Tanabe Pharma America, Inc. 2017-05-05 Not applicable US Radicava Solution 30 mg / 100 mL Intravenous Mitsubishi Tanabe Pharma Corporation 2019-10-29 Not applicable Canada 
Radicava Ors Kit; Suspension 1050 mg/50mL Oral Mitsubishi Tanabe Pharma America, Inc. 2022-05-12 Not applicable US Radicava Ors Kit; Suspension 735 mg/35mL Oral Mitsubishi Tanabe Pharma America, Inc. 2022-05-12 Not applicable US
Categories
- ATC Codes
- N07XX14 — Edaravone
- Drug Categories
- Antioxidants
- Central Nervous System Agents
- Compounds used in a research, industrial, or household setting
- Free Radical Scavengers
- Miscellaneous Central Nervous System Agents
- Nervous System
- Neuroprotective Agents
- OAT1/SLC22A6 Substrates
- OAT3/SLC22A8 Substrates
- Protective Agents
- Pyrazoles
- Pyrazolones
- UGT1A1 Substrates
- UGT1A6 substrate
- UGT1A9 Substrates
- UGT2B17 substrates
- UGT2B7 substrates
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrazolones. These are compounds containing a pyrazole ring which bears a ketone.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolines
- Sub Class
- Pyrazolines
- Direct Parent
- Pyrazolones
- Alternative Parents
- Benzene and substituted derivatives / Carboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid derivative / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- ring assembly (CHEBI:31530)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S798V6YJRP
- CAS number
- 89-25-8
- InChI Key
- QELUYTUMUWHWMC-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
- IUPAC Name
- 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one
- SMILES
- CC1=NN(C(=O)C1)C1=CC=CC=C1
References
- General References
- Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ, Liu J, Zhu C, Shen LL, Liu CH, Wang YR, Zeng GH, Parikh A, Chen J, Liang CR, Xiang Y, Bu XL, Deng J, Li J, Xu J, Zeng YQ, Xu X, Xu HW, Zhong JH, Zhou HD, Zhou XF, Wang YJ: Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5225-30. doi: 10.1073/pnas.1422998112. Epub 2015 Apr 6. [Article]
- Li H, Xu K, Wang Y, Zhang H, Li T, Meng L, Gong X, Zhang H, Ou N, Ruan J: Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. Drugs R D. 2012 Jun 1;12(2):65-70. doi: 10.2165/11634290-000000000-00000. [Article]
- Watanabe T, Tahara M, Todo S: The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008 Summer;26(2):101-14. doi: 10.1111/j.1527-3466.2008.00041.x. [Article]
- Kikuchi K, Uchikado H, Miyagi N, Morimoto Y, Ito T, Tancharoen S, Miura N, Miyata K, Sakamoto R, Kikuchi C, Iida N, Shiomi N, Kuramoto T, Kawahara K: Beyond neurological disease: new targets for edaravone (Review). Int J Mol Med. 2011 Dec;28(6):899-906. doi: 10.3892/ijmm.2011.795. Epub 2011 Sep 15. [Article]
- Cruz MP: Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T. 2018 Jan;43(1):25-28. [Article]
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Health Canada Approved Drug Products: RADICAVA (edaravone) oral suspension [Link]
- Cayman Chemical: Edaravone MSDS [Link]
- CymitQuimica: Edaravone MSDS [Link]
- EMA: Radicava; Withdrawal of the marketing authorisation application [Link]
- EMA Withdrawal assessment report: Radicava [Link]
- The Pharma Letter: Mitsubishi Tanabe pulls Radicava MAA for ALS in the Europe [Link]
- Newswire: MITSUBISHI TANABE PHARMA CANADA ANNOUNCES CANADIAN AUTHORIZATION OF RADICAVA® (EDARAVONE) ORAL SUSPENSION FOR THE TREATMENT OF PATIENTS WITH ALS [Link]
- External Links
- Human Metabolome Database
- HMDB0251697
- KEGG Drug
- D01552
- KEGG Compound
- C13008
- PubChem Compound
- 4021
- PubChem Substance
- 347828521
- ChemSpider
- 3881
- BindingDB
- 50200541
- 1921877
- ChEBI
- 31530
- ChEMBL
- CHEMBL290916
- ZINC
- ZINC000018203737
- PDBe Ligand
- W1P
- Wikipedia
- Edaravone
- PDB Entries
- 5s3i / 5s52
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Cerebral Infarctions 1 4 Completed Treatment Cerebrovascular Accident 1 4 Completed Treatment Myocardial Infarction / Reperfusion Injury 1 3 Active Not Recruiting Treatment Amyotrophic Lateral Sclerosis (ALS) 1 3 Completed Treatment Acute Ischemic Stroke 1 3 Completed Treatment Amyotrophic Lateral Sclerosis (ALS) 5 3 Recruiting Treatment Acute Ischemic Stroke / Edaravone Dexborneol / Mechanical Thrombectomy / Phase III 1 3 Recruiting Treatment Amyotrophic Lateral Sclerosis (ALS) 3 2 Completed Treatment Acute Ischemic Stroke 2 2 Completed Treatment Cerebrovascular Accident / Endovascular Thrombectomy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous 30 mg/100mL Injection Intravenous 60 mg/100mL Injection, solution, concentrate Intravenous Solution Intravenous 30 mg / 100 mL Kit; suspension Oral 1050 mg/50mL Kit; suspension Oral 735 mg/35mL Solution Intravenous 30 mg/20mL - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6933310 No 2005-08-23 2020-11-13 US US11241416 No 2019-11-01 2039-11-01 US US10987341 No 2021-04-27 2039-11-01 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 129.7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215446s000lbl.pdf boiling point (°C) 287 https://cdn.caymanchem.com/cdn/msds/13320m.pdf logP 1.12 https://static.cymitquimica.com/products/04/pdf/sds-C13105000.pdf pKa 7.0 Watanabe T, Tahara M, Todo S: The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008 Summer;26(2):101-14. doi: 10.1111/j.1527-3466.2008.00041.x. [A19140] - Predicted Properties
Property Value Source Water Solubility 0.939 mg/mL ALOGPS logP 0.53 ALOGPS logP 1.53 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 13.45 Chemaxon pKa (Strongest Basic) -1.5 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 32.67 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 49.49 m3·mol-1 Chemaxon Polarizability 18.61 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-004i-1900000000-9c17dd936441a10926dc
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Steroid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
- Gene Name
- UGT1A1
- Uniprot ID
- P22309
- Uniprot Name
- UDP-glucuronosyltransferase 1-1
- Molecular Weight
- 59590.91 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Protein homodimerization activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks trans...
- Gene Name
- UGT1A6
- Uniprot ID
- P19224
- Uniprot Name
- UDP-glucuronosyltransferase 1-6
- Molecular Weight
- 60750.215 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
- Gene Name
- UGT1A7
- Uniprot ID
- Q9HAW7
- Uniprot Name
- UDP-glucuronosyltransferase 1-7
- Molecular Weight
- 59818.315 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Steroid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
- Gene Name
- UGT1A8
- Uniprot ID
- Q9HAW9
- Uniprot Name
- UDP-glucuronosyltransferase 1-8
- Molecular Weight
- 59741.035 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
- Gene Name
- UGT1A9
- Uniprot ID
- O60656
- Uniprot Name
- UDP-glucuronosyltransferase 1-9
- Molecular Weight
- 59940.495 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Protein kinase c binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
- Gene Name
- UGT1A10
- Uniprot ID
- Q9HAW8
- Uniprot Name
- UDP-glucuronosyltransferase 1-10
- Molecular Weight
- 59809.075 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
- Gene Name
- UGT2B7
- Uniprot ID
- P16662
- Uniprot Name
- UDP-glucuronosyltransferase 2B7
- Molecular Weight
- 60694.12 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbe...
- Gene Name
- UGT2B17
- Uniprot ID
- O75795
- Uniprot Name
- UDP-glucuronosyltransferase 2B17
- Molecular Weight
- 61094.915 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sulfotransferase activity
- Specific Function
- Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfonation of steroids and bile acids in the liver and adrenal glands.
Components:
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Substrate profile was investigated in vitro using HEK293 cells.
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Substrate activity was demonstrated in vitro using HEK293 cells.
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [Article]
Drug created at October 20, 2016 21:42 / Updated at December 01, 2022 11:27